Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 687 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Charity promotes eco-fashion with collection at Love Not Landfill pop-up November 12, 2021 Why the Bone Marrow Registry Needs More Diverse Donors and How... March 30, 2021 New drug combo for advanced breast cancer approved for NHS in... August 12, 2021 A new target to slow down ageing and reduce blood cancer... June 29, 2023 Load more HOT NEWS 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout New on NCI’s Websites for September 2020 FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma Teclistamab Shows Promise for People with Heavily Pretreated Multiple Myeloma
